Adcentrx Commences Phase 1a/b Trial for Solid Tumor Therapy

Adcentrx Therapeutics (Adcentrx), a biotechnology company in clinical development focused on pioneering protein conjugates for cancer and other serious diseases, announced that the first patient has been dosed in the phase 1a/b trial of ADRX-0405 for advanced solid tumour therapy.

“Advancing our second program into clinical trials marks an important milestone for Adcentrx and further validates the potential of our ADC technology platform,” said Hui Li, Ph.D., founder and chief executive officer of Adcentrx. “STEAP1 is an attractive ADC target, and we are excited about the first-in-class potential for ADRX-0405. We believe this novel ADC offers a unique approach to treating patients with STEAP1-expressing cancers, such as metastatic castration-resistant prostate cancer, where a significant unmet need remains for new targeted therapies.”

The initial phase 1a/b clinical trial of ADRX-0405 is an open-label study focused on dose escalation and expansion, taking place at various locations in the US. This trial is recruiting patients with specific advanced solid tumors, aiming primarily to assess the safety and tolerability of ADRX-0405 while identifying its optimal dosing regimen. The firm expects to provide an initial data readout in the fourth quarter of 2025.

ADRX-0405 is a novel antibody-drug conjugate (ADC) made up of a humanized IgG1 antibody that targets the six-transmembrane epithelial antigen of the prostate 1 (STEAP1). This cell surface protein is overexpressed in prostate cancer and some other malignancies but is minimally present in normal healthy tissues.